Trial · NCT07262983
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT07262983, Phase 1, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis. Trials, record NCT07262983. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07262983
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
- NCT number
- NCT07262983
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
- Interventions
- baricitinib
- First posted
- 2025-12-04
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of SAEs, AEs requiring study drug discontinuation. | Through end of study | To determine the safety and tolerability of JAK inhibitor treatment (baricitinib) in patients with Job s syndrome with lupus-like disease and/or AD. |
| Secondary | Incidence of Candida and/or bacterial infections. | Through end of study | To assess changes in Candida and/or bacterial infections |
| Secondary | Mean change in CLASI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features. |
| Secondary | Mean change in EASI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on AD. |
| Secondary | Mean change in SLEDAI score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features. |
| Secondary | Mean change in the PGA score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To evaluate the effect of baricitinib on lupus-like features and AD. |
| Secondary | Mean change in the SF-36 score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the PROMIS score from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the DLQI score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
| Secondary | Mean change in the CDLQI score (pediatrics) from day -90 to day 0 and then from day 0 to days 90 and 180. | From day -90 to day 0 and then from day 0 to days 90 and 180 | To investigate the effect of baricitinib on QOL. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07262983
GET https://conductscience.org/api/trials/v1/NCT07262983/registered